Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
180 Life Sciences Corp
(NQ:
ATNF
)
1.750
-0.120 (-6.42%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 180 Life Sciences Corp
< Previous
1
2
3
Next >
BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Appoints Omar Jimenez as Chief Financial Officer
September 13, 2024
Via
Investor Brand Network
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
September 12, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Reports on Human Clinical Trial Evaluating Solid Formulation of CBD with Enhanced Oral Uptake
July 30, 2024
Via
Investor Brand Network
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
July 30, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Granted Additional Extension to Regain Compliance with Continued Nasdaq Listing Requirements
July 23, 2024
Via
Investor Brand Network
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
July 23, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
July 02, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 14, 2024
Via
Investor Brand Network
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
March 14, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Plans 1-for-19 Reverse Stock Split to Regain NASDAQ Compliance
February 26, 2024
Via
Investor Brand Network
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
February 26, 2024
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Engagement of Alliance Global Partners
December 04, 2023
Via
Investor Brand Network
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
December 04, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Officials, Board to Review of Strategic Alternatives
November 28, 2023
Via
Investor Brand Network
180 Life Sciences Announces Review of Strategic Alternatives
November 28, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Public Offering
August 15, 2023
Via
Investor Brand Network
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
August 14, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Public Offering Pricing, Offering Could Reach $3M
August 10, 2023
Via
Investor Brand Network
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
August 10, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters Agreement for Strategic PK Study
August 07, 2023
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
August 07, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Update on Regulatory Approval Process for Dupuytren’s Disease Treatment
August 03, 2023
Via
Investor Brand Network
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
August 03, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
July 31, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
July 31, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Registered Direct Offering, Concurrent Private Placement
April 11, 2023
Via
Investor Brand Network
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
April 10, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $3M Registered Direct, Concurrent Private Placement
April 05, 2023
Via
Investor Brand Network
180 Life Sciences Corp. (NASDAQ: ATNF) Near the Top of Equities by Percentage Gain on 4/5
April 05, 2023
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
April 05, 2023
Priced At-The-Market Under Nasdaq Rules
From
180 Life Sciences Corp.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.